Insulin glulisine: preclinical hallmarks and clinical efficacy

ISSN： 1475-0708

Source： Therapy, Vol.6, Iss.2, 2009-03, pp. : 209-229

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Emerging Role of Complement C3 as A Biomarker of Insulin Resistance and Cardiometabolic Diseases: Preclinical and Clinical Evidence

Reviews on Recent Clinical Trials, Vol. 13, Iss. 1, 2018-01 ,pp. : 61-68

Bentham Science Publishers

Access to resources Recommend Favorite

Biomechanics: Preclinical and clinical

By Burr David

Clinical Review in Bone and Mineral Metabolism, Vol. 4, Iss. 3, 2006-09 ,pp. : 155-166

Humana Press, Inc

Access to resources Recommend Favorite

Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24‐week, randomized, open‐label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape)

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 12, 2015-12 ,pp. : 1133-1141

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long-term efficacy of insulin glargine therapy with an educational programme in type 1 diabetes patients in clinical practice

By Schreiber Stephan A. Russmann Anika

Current Medical Research and Opinion, Vol. 23, Iss. 12, 2007-12 ,pp. : 3131-3136

Informa Healthcare

Access to resources Recommend Favorite

TAS-106: Preclinical, Clinical and Beyond

Oncology, Vol. 85, Iss. 6, 2013-12 ,pp. : 356-363

Karger

Access to resources Recommend Favorite